Treatment of essential tremor with the barbiturate t2000 (1,3‐dimethoxymethyl‐5,5‐diphenyl‐barbituric acid)
Identifieur interne : 001679 ( Istex/Curation ); précédent : 001678; suivant : 001680Treatment of essential tremor with the barbiturate t2000 (1,3‐dimethoxymethyl‐5,5‐diphenyl‐barbituric acid)
Auteurs : Calvin Melmed [Canada] ; Daniel Moros [États-Unis] ; Howard Rutman [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-04-15.
English descriptors
Abstract
The effect of the barbiturate T2000 (1,3‐dimethoxymethyl‐5,5‐diphenyl‐barbituric acid; DMMDPB) on essential tremor, given in twice daily doses of 400 and 300 mg, was assessed in two brief, randomized, placebo‐controlled, parallel‐group, double‐blinded, single‐center trials in 12 and 22 patients, respectively. These trials represent the first clinical use of T2000 for a specific indication. The primary endpoint was the change in the mean scores of the treated and control groups based on the Fahn‐Tolosa‐Marin tremor scale. In the first study of 12 patients treated with 400 mg or placebo twice daily for 14 days, the mean change from baseline at day 14 was 19.3 (P < 0.0001) in the treated group and 9.0 (P = 0.0121) in the control group. Using a two‐factor mixed ANOVA model to evaluate within group and between group changes, the effect of T2000 was significantly different from that of the placebo group (P = 0.03). In the second study of 22 patients treated with 300 mg of T2000 or placebo twice daily for 20 days, statistically significant changes were seen in treated patients compared to baseline, but the ANOVA model did not demonstrate a significant treatment effect of T2000 compared to placebo. When the treated groups from each study are compared, the 800‐mg daily group is significantly different from the 600‐mg daily group (P = 0.02). Some treated patients in each study, but no placebo patients, experienced marked improvement. These results support further evaluation of T2000 in the treatment of essential tremor. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21321
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001679
Links to Exploration step
ISTEX:9F200C0F1CBCD07EFFACBA633162EDD1F97CED07Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of essential tremor with the barbiturate t2000 (1,3‐dimethoxymethyl‐5,5‐diphenyl‐barbituric acid)</title><author><name sortKey="Melmed, Calvin" sort="Melmed, Calvin" uniqKey="Melmed C" first="Calvin" last="Melmed">Calvin Melmed</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurosciences, SMBD‐Jewish General Hospital, Montreal, Quebec, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurosciences, SMBD‐Jewish General Hospital, Montreal, Quebec</wicri:regionArea></affiliation></author><author><name sortKey="Moros, Daniel" sort="Moros, Daniel" uniqKey="Moros D" first="Daniel" last="Moros">Daniel Moros</name><affiliation wicri:level="1"><mods:affiliation>Taro Pharmaceuticals USA Inc., Hawthorne, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Taro Pharmaceuticals USA Inc., Hawthorne, New York</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York City, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York City, New York</wicri:regionArea></affiliation></author><author><name sortKey="Rutman, Howard" sort="Rutman, Howard" uniqKey="Rutman H" first="Howard" last="Rutman">Howard Rutman</name><affiliation wicri:level="1"><mods:affiliation>Taro Pharmaceuticals USA Inc., Hawthorne, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Taro Pharmaceuticals USA Inc., Hawthorne, New York</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Albert Einstein College of Medicine of Yeshiva University, Bronx, New York</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9F200C0F1CBCD07EFFACBA633162EDD1F97CED07</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21321</idno><idno type="url">https://api.istex.fr/document/9F200C0F1CBCD07EFFACBA633162EDD1F97CED07/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001679</idno><idno type="wicri:Area/Istex/Curation">001679</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of essential tremor with the barbiturate t2000 (1,3‐dimethoxymethyl‐5,5‐diphenyl‐barbituric acid)</title><author><name sortKey="Melmed, Calvin" sort="Melmed, Calvin" uniqKey="Melmed C" first="Calvin" last="Melmed">Calvin Melmed</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurosciences, SMBD‐Jewish General Hospital, Montreal, Quebec, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurosciences, SMBD‐Jewish General Hospital, Montreal, Quebec</wicri:regionArea></affiliation></author><author><name sortKey="Moros, Daniel" sort="Moros, Daniel" uniqKey="Moros D" first="Daniel" last="Moros">Daniel Moros</name><affiliation wicri:level="1"><mods:affiliation>Taro Pharmaceuticals USA Inc., Hawthorne, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Taro Pharmaceuticals USA Inc., Hawthorne, New York</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York City, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York City, New York</wicri:regionArea></affiliation></author><author><name sortKey="Rutman, Howard" sort="Rutman, Howard" uniqKey="Rutman H" first="Howard" last="Rutman">Howard Rutman</name><affiliation wicri:level="1"><mods:affiliation>Taro Pharmaceuticals USA Inc., Hawthorne, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Taro Pharmaceuticals USA Inc., Hawthorne, New York</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Albert Einstein College of Medicine of Yeshiva University, Bronx, New York</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-04-15">2007-04-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="723">723</biblScope><biblScope unit="page" to="727">727</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9F200C0F1CBCD07EFFACBA633162EDD1F97CED07</idno><idno type="DOI">10.1002/mds.21321</idno><idno type="ArticleID">MDS21321</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>T2000</term><term>barbiturate</term><term>dimethoxymethyl‐diphenyl‐barbituric acid</term><term>essential tremor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The effect of the barbiturate T2000 (1,3‐dimethoxymethyl‐5,5‐diphenyl‐barbituric acid; DMMDPB) on essential tremor, given in twice daily doses of 400 and 300 mg, was assessed in two brief, randomized, placebo‐controlled, parallel‐group, double‐blinded, single‐center trials in 12 and 22 patients, respectively. These trials represent the first clinical use of T2000 for a specific indication. The primary endpoint was the change in the mean scores of the treated and control groups based on the Fahn‐Tolosa‐Marin tremor scale. In the first study of 12 patients treated with 400 mg or placebo twice daily for 14 days, the mean change from baseline at day 14 was 19.3 (P < 0.0001) in the treated group and 9.0 (P = 0.0121) in the control group. Using a two‐factor mixed ANOVA model to evaluate within group and between group changes, the effect of T2000 was significantly different from that of the placebo group (P = 0.03). In the second study of 22 patients treated with 300 mg of T2000 or placebo twice daily for 20 days, statistically significant changes were seen in treated patients compared to baseline, but the ANOVA model did not demonstrate a significant treatment effect of T2000 compared to placebo. When the treated groups from each study are compared, the 800‐mg daily group is significantly different from the 600‐mg daily group (P = 0.02). Some treated patients in each study, but no placebo patients, experienced marked improvement. These results support further evaluation of T2000 in the treatment of essential tremor. © 2006 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001679 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001679 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:9F200C0F1CBCD07EFFACBA633162EDD1F97CED07
|texte= Treatment of essential tremor with the barbiturate t2000 (1,3‐dimethoxymethyl‐5,5‐diphenyl‐barbituric acid)
}}
| This area was generated with Dilib version V0.6.23. |  |